Hello Part-time Trader…👋

U.S. stocks were gaining in the premarket today following the attempted assassination of presidential candidate Donald Trump. Despite the attack on former President Trump in Pennsylvania on Saturday, markets don’t appear to be rattled.

Bond yields showed mixed results. The yield on the benchmark 10-year U.S. Treasury bond was at 4.215% early Monday, compared to 4.186% on Friday. The yield on the 2-year note was at 4.453%, compared to 4.531% at the end of last week.

Bitcoin surged in early-morning trading Monday as markets reacted to the shooting of former President Donald Trump. Other cryptocurrencies also rose, including Ether, Solana, Cardano, and Dogecoin. Crypto stocks were also buoyed, with Coinbase and Microstrategy seeing gains.

Happening Today

✓ 08:30 AM ET – NY Empire State Manufacturing Index (Jul)

✓ 12:30 PM ET – Fed Chair Powell Speaks

✓ 04:35 PM ET – FOMC Member Daly Speaks

PREMARKET SNAPSHOT 📈

Market futures are showing positive movement, with the S&P 500, Dow, and NASDAQ all posting gains.

SECTOR SNAPSHOT ✨

The market put on a strong performance with nearly all sectors showing gains. Consumer Discretionary and Information Technology led the way with solid increases, followed by robust performances in Health Care, Materials, and Industrials. Even traditionally steady sectors like Consumer Staples and Utilities saw positive movements. However, Communication Services faced a slight decline, standing out as the day's underperformer. Overall, the market sentiment was upbeat, reflecting broad-based optimism.

PreMarket Unusual Volume Stocks

📈 DatChat Inc (DATS): DatChat Inc saw an extraordinary surge in trading activity with a volume of 14,277,069, far surpassing its average volume of 156.41. This massive uptick in interest resulted in a significant 112.50% price change, reflecting heightened market interest.

📈 Mira Pharmaceuticals Inc (MIRA): Mira Pharmaceuticals Inc experienced a substantial rise in volume, trading 3,209,825 shares compared to its average of 114.26. This dramatic increase in trading volume resulted in a 64.19% price change, indicating strong investor activity.

📈 Crown LNG Holdings Ltd (CGBS): Crown LNG Holdings Ltd saw its trading volume surge to 4,283,951, significantly higher than its average of 321.93. The stock's price change of 8.45% mirrors this spike in trading volume.

📈 Phunware Inc (PHUN): Phunware Inc's volume spiked to 2,253,858, a substantial increase from its average of 364.42. The stock's 33.96% price change highlights the impact of the increased trading activity.

📈 Scinai Immunotherapeutics Ltd ADR (SCNI): Scinai Immunotherapeutics Ltd ADR saw its volume rise to 2,405,271, far exceeding its average of 564.43. The stock's 55.17% price change reflects the surge in trading volume.

Premarket Picks

MIRA Pharmaceuticals (MIRA) soared nearly 49% to almost $0.88 per share in pre-market after promising results from tests of their drug MIRA-55.

Sinai Immunotherapeutics (SCNI) also rose almost 49% to $6.04 per share in pre-market on news of positive results in their research on psoriasis.

Trump Media & Technology Group (DJT) gained nearly 47% to over $45.32 per share, likely due to investor reaction to a recent attack on Donald Trump.

Shineco (SISI) saw a more modest pre-market increase of 13% to $0.95 per share after announcing the pricing of a public offering to raise $2 million.

Below is a list of other hot stocks in pre-market today:

Important FDA 

Recently Announced

Arcutis Biotherapeutics (ARQT) got a thumbs up from the FDA on July 9th, 2024! Their Roflumilast Cream, which is at 0.15% concentration, is now approved to treat mild to moderate eczema in adults and kids six years old and up. Eczema is another term for atopic dermatitis.

Rocket Pharmaceuticals (RCKT) had a bit of a hurdle to overcome on June 28th, 2024. The FDA asked for more information about their KRESLADI treatment before they could approve it. This means Rocket Pharmaceuticals needs to do some additional work before they can try again for approval.

There was some good news for AbbVie (ABBV) on June 26th, 2024! Their Epcoritamab-bysp treatment for a certain type of lymphoma got the green light from the FDA. This is a win for both AbbVie and cancer patients who can benefit from this treatment.

Upcoming Announcements

Phathom Pharmaceuticals (PHAT) investors should be on the lookout for July 19th, 2024. The FDA is set to announce their decision on that day regarding the approval of VOQUEZNA Tablets. This medication is designed to treat heartburn associated with non-erosive GERD.

For investors in AstraZeneca (AZN), another important date to remember is July 25th, 2024. A panel of experts will convene on that date to evaluate IMFINZI, a lung cancer treatment. Specifically, the focus will be on IMFINZI's effectiveness when used with chemotherapy before surgery (neoadjuvant treatment) and on its own after surgery, for adults with resectable non-small cell lung cancer.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.